A discrete choice experiment of treatment preferences for patients with chronic glomerulonephritis in Japan

Abstract Background Novel drugs for chronic glomerulonephritis (CGN) are becoming available. As treatment options increase, those that address or meet the preferences of patients with CGN may also improve treatment satisfaction and clinical outcomes. The objective of this study was to identify patient preferences for CGN treatments in Japan. Methods This study was a web-based questionnaire survey using a discrete choice experiment (DCE) among patients with CGN in Japan. Eligible patients were adults residing in Japan who reported a biopsy-confirmed diagnosis of CGN, were receiving outpatient treatment, and had visited a hospital for CGN within the previous year. Patients undergoing dialysis were excluded. The following attributes were evaluated using a DCE: effect of treatment on estimated glomerular filtration rate (eGFR), period of confirmed safety, frequency and administration method, and monthly copayment. Results Of 286 patients with CGN, 187 (65.4%) were diagnosed with IgA nephropathy. Among the attributes and levels evaluated, the effect of treatment on eGFR had the highest relative importance in the selection of novel treatments, followed by monthly copayment and frequency and administration method. Patients exhibited a preference for non-invasive oral formulations over injectable formulations. In addition, 92.0% of patients expressed a desire to receive information from their physicians on novel treatments once available. Conclusions Given the attributes and level ranges evaluated in this study, our results indicate that patients with CGN in Japan prefer novel treatments with high efficacy regarding eGFR, low copayments, and non-invasive oral formulations. The desire for information about new drugs may reflect patients’ interest in exploring novel therapeutic options. These results may help inform the development of patient-centered treatment plans that consider or meet the preferences of patients with CGN in Japan.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2026-11-12
DOI
https://doi.org/10.1186/s12882-026-05495-8
Primary Topic
Economic and Environmental Valuation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A discrete choice experiment of treatment preferences for patients with chronic glomerulonephritis in Japan

Shunsuke Eguchi, Yuta Fukuoka, Kazuma Iekushi, Ai Tsuyuki et al.
BMC Nephrology
Economic and Environmental Valuation
article

A discrete choice experiment of treatment preferences for patients with chronic glomerulonephritis in Japan

Shunsuke Eguchi, Yuta Fukuoka, Kazuma Iekushi, Ai Tsuyuki, Masao Kikuchi, Keigo Hanada, Naoya Itoh
article en

Abstract

Abstract Background Novel drugs for chronic glomerulonephritis (CGN) are becoming available. As treatment options increase, those that address or meet the preferences of patients with CGN may also improve treatment satisfaction and clinical outcomes. The objective of this study was to identify patient preferences for CGN treatments in Japan. Methods This study was a web-based questionnaire survey using a discrete choice experiment (DCE) among patients with CGN in Japan. Eligible patients were adults residing in Japan who reported a biopsy-confirmed diagnosis of CGN, were receiving outpatient treatment, and had visited a hospital for CGN within the previous year. Patients undergoing dialysis were excluded. The following attributes were evaluated using a DCE: effect of treatment on estimated glomerular filtration rate (eGFR), period of confirmed safety, frequency and administration method, and monthly copayment. Results Of 286 patients with CGN, 187 (65.4%) were diagnosed with IgA nephropathy. Among the attributes and levels evaluated, the effect of treatment on eGFR had the highest relative importance in the selection of novel treatments, followed by monthly copayment and frequency and administration method. Patients exhibited a preference for non-invasive oral formulations over injectable formulations. In addition, 92.0% of patients expressed a desire to receive information from their physicians on novel treatments once available. Conclusions Given the attributes and level ranges evaluated in this study, our results indicate that patients with CGN in Japan prefer novel treatments with high efficacy regarding eGFR, low copayments, and non-invasive oral formulations. The desire for information about new drugs may reflect patients’ interest in exploring novel therapeutic options. These results may help inform the development of patient-centered treatment plans that consider or meet the preferences of patients with CGN in Japan.

BMC Nephrology
University of Miyazaki (JP), Novartis (Japan) (JP), Crecon Medical Assessment Inc. (Japan) (JP)
Novartis Japan
Good health and well-being
Economic and Environmental Valuation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon